apo-gliclazide mr 30mg tablets, bottle
arrotex pharmaceuticals pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: stearic acid; hypromellose; colloidal anhydrous silica - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose. during controlled clinical trials in patients with type ii diabetes, gliclazide mr 30 mg tablets, taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.
apo-gliclazide mr 30mg tablets, blister pack
arrotex pharmaceuticals pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: hypromellose; stearic acid; colloidal anhydrous silica - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose. during controlled clinical trials in patients with type ii diabetes, gliclazide mr 30 mg tablets, taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.
apo-gliclazide gliclazide 80mg tablet blister pack
arrotex pharmaceuticals pty ltd - gliclazide, quantity: 80 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica - indicated for the treatment of diabetes mellitus of the maturity onset type, which cannot be controlled by diet alone.
gliclazide lupin mr gliclazide 60 mg modified release tablet blister pack
lupin australia pty limited - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: povidone; calcium hydrogen phosphate dihydrate; hypromellose; magnesium stearate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.
apo-gliclazide mr 60 mg tablets
pharmaforte (malaysia) sdn. bhd. - gliclazide -
ardix gliclazide 60 mg mr gliclazide 60 mg tablet blister pack
servier laboratories (aust) pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; maltodextrin; hypromellose - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose. during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg-120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.
mylan-gliclazide mr tablet (extended-release)
mylan pharmaceuticals ulc - gliclazide - tablet (extended-release) - 30mg - gliclazide 30mg - sulfonylureas
taro-gliclazide mr tablet (extended-release)
sun pharma canada inc - gliclazide - tablet (extended-release) - 60mg - gliclazide 60mg - sulfonylureas
taro-gliclazide mr tablet (extended-release)
sun pharma canada inc - gliclazide - tablet (extended-release) - 30mg - gliclazide 30mg - sulfonylureas
apo-gliclazide mr tablet (extended-release)
apotex inc - gliclazide - tablet (extended-release) - 30mg - gliclazide 30mg - sulfonylureas